Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Bioorganic & Medicinal Chemistry Letters|July 26, 2011
Discovery of N-(1-adamantyl)-2-(4-alkylpiperazin-1-yl)acetamide derivatives as T-type calcium channel (Cav3.2) inhibitorsFabrizio Giordanetto, Laurent Knerr, Nidhal Selmi, et al.Bioorganic & Medicinal Chemistry Letters|December 4, 2012
Discovery of N-[[1-[2-(tert-butylcarbamoylamino)ethyl]-4-(hydroxymethyl)-4-piperidyl]methyl]-3,5-dichloro-benzamide as a selective T-type calcium channel (Cav3.2) inhibitorFabrizio Giordanetto, Andreas Wållberg, Laurent Knerr, et al.Journal of Biomolecular Screening|July 15, 2015
A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay ParadigmBernard Fermini, Jules C Hancox, Najah Abi-Gerges, et al.Scientific Reports|March 30, 2020
Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.Scientific Reports|July 16, 2020
Publisher Correction: Cross-site and cross-platform variability of automated patch clamp assessments of drug effects on human cardiac currents in recombinant cellsJames Kramer, Herbert M Himmel, Anders Lindqvist, et al.Toxicology and Applied Pharmacology|March 27, 2020
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigmBradley J Ridder, Derek J Leishman, Matthew Bridgland-Taylor, et al.Pageof 2